Kamal Hamed - 12 Jun 2023 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Signature
/s/ Tamara Joseph. Attorney-in-Fact for Kamal Hamed
Issuer symbol
SPRO
Transactions as of
12 Jun 2023
Net transactions value
$0
Form type
4
Filing time
14 Jun 2023, 08:30:39 UTC
Previous filing
03 Feb 2023
Next filing
15 Sep 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +140,000 +29% $0.000000 615,957 12 Jun 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 4, 2022, the Reporting Person was granted a target of 140,000 performance-based restricted stock units ("RSUs") under the Issuer's 2019 Inducement Equity Incentive Plan, as amended. Each RSU represents the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On June 12, 2023, the Board of Directors of the Issuer determined that 100% of the performance-based conditions were met resulting in 140,000 RSUs earned by the Reporting Person. The RSUs vest in two equal annual installments on September 12, 2023 and September 12, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Consists of RSUs held by the Reporting Person.